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It is demonstrated here that osteocalcin, the Gla-containing protein from bone, is unable to interfere with 
the binding of the blood coagulation factors to phospholipid vesicles. Therefore, it seems that besides the 
Gla residues other structural features of the coagulation factors are required for their effective binding to 
phospholipid surfaces. 
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1. INTRODUCTION 
Since the discovery of Gla it has been frequently 
suggested that the Gla residues in the 4 ‘vitamin K- 
dependent’ coagulation factors are directly in- 
volved in the binding of these factors to negatively 
charged phospholipid surfaces. The presumed 
binding of the Gla residues was thought to occur 
via Ca2+ [l-4]. S’ mce the number of high-affinity 
calcium-binding sites more or less equals the 
amount of Gla residues in the coagulation factors 
[l-5], it was assumed that one Ca2+ is centered 
between the two carboxyl groups of Gla and two 
negatively charged phospholipids, as represented 
in fig.1. Although the formation of this 
hypothetical complex is not theoretically impossi- 
ble, the question remains as to how one Ca*+ can 
sufficiently neutralize the 4 negative charges in this 
complex. One would rather think that after Ca*+ 
has been bound to a Gla residue, the resulting 
Gla*- - Ca*+ complex has no net charge and hence 
is not involved in the binding of the protein to 
negatively charged phospholipid surfaces. 
possibility by determining whether the activation 
of blood coagulation factors at limiting 
phospholipid concentrations is inhibited by 
purified osteocalcin and present here the results. 
2. MATERIALS AND METHODS 
Bovine osteocalcin was prepared as described 
for decarboxylated osteocalcin [6] except that the 
Secondly, a consequence of the model proposed 
in fig.1 is that Gla-containing proteins which are 
not involved in blood coagulation should also be 
able to bind to phospholipids and compete with the 
coagulation factors for binding sites on the 
phospholipid surface. We have examined this 
Fig.1. Hypothetical model for the binding of a Gla 
residue to negatively charged phospholipids. 
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decarboxylation step was omitted. The presence of 
osteocalcin in the various preparations was tested 
with the aid of a radioimmunoassay (Immunonuc- 
lear). 
Bovine coagulation factors II (prothrombin) and 
X were prepared as in [7] and factor X was ac- 
tivated with Russell’s viper venom [8]. The activa- 
tion of prothrombin in a purified system was 
measured with a chromogenic assay [7] at 37°C in 
reaction mixtures containing 0.175 M NaCl, 
0.05 M Tris-HCl (pH 7.9), 0.25 PM prothrombin, 
1 nM factor Xa, 10 mM CaC12, 50 pM phospholi- 
pid (sonicated vesicles containing 20% 18 : 1 
phosphatidylserine and 80% 18 : 1 phosphatidyl- 
choline, 0.47 mM chromogenic substrate S2238 
(AB Kabi Diagnostica) and osteocalcin as in- 
dicated. The reaction mixtures were preincubated 
for 5 min at 37°C in the absence of factor Xa. 
The coagulation times in plasma were deter- 
mined with a one-stage coagulation assay using 
normal titrated bovine plasma and various dilu- 
tions of bovine thromboplastin [9]. 
3. RESULTS 
3.1. The effect of osteocalcin in a purified 
prothrombinase assay system 
Using purified bovine coagulation factors and a 
limiting concentration of phospholipid vesicles, 
the activation of prothrombin by activated factor 
X was measured in the absence and presence of 
various concentrations of osteocalcin. The rate of 
Table 1 
Activation of prothrombin in the absence and presence 
of osteocalcin 
Time elapsed since Prothrombin activation rate 
start of the reaction (mol IIa formed/min 
(min) per mol Xa) 
A B C 
2 1.21 1.26 1.26 
4 1.21 1.24 1.30 
6 1.17 1.22 1.25 
The osteocalcin concentrations were O/rM (A), 1OpM 
(B) and 2OOpM (C). The data are the means of two 
duplicate experiments. Experimental details are given in 
section 2 
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thrombin formation was measured in duplicate ex- 
periments and after 3 different incubation periods 
(table 1). At the highest concentration the excess of 
osteocalcin was SOO-fold with respect o prothrom- 
bin and 200000-fold with respect to activated fac- 
tor X. Nevertheless these amounts of osteocalcin 
did not influence the rate of prothrombin 
activation. 
3.2. The effect of osteocalcin on the coagulation 
time of plasma 
Using bovine plasma and decreasing concentra- 
tions of thromboplastin we also measured the ef- 
fect of osteocalcin on the rate of clot formation in 
whole plasma. By using various dilutions of 
thromboplastin, in this experiment a system was 
also created in which the concentration of 
phospholipids was rate-determining. It was 
checked that the addition of purified phospholi- 
pids (vesicles containing 4 PM phosphatidylserine 
and 16pM phosphatidylcholine) to such a system 
caused a substantial decrease in clotting time. As 
shown in fig.2, up to a concentration of 0.5 mM 
osteocalcin did not influence the coagulation time 
of plasma. Since the plasma concentrations of pro- 
thrombin, factor X and factor VII are 2, 0.2 and 
less than O.O2pM, respectively [3,8,10], this ex- 
periment demonstrates again that even if 
osteocalcin does possess a certain affinity towards 
phospholipids, this affinity is more than 3-5 
i 
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Fig.2. The influence of osteocalcin on the coagulation 
time of plasma. The osteocalcin concentrations were 
0 mM (M), 0.1 mM (C--O), 0.25 mM (w) and 
0.5 mM (ti). The one-stage coagulation times were 
measured at increasing dilutions of thromboplastin 
buffer A (0.1 M NaCl, 0.05 M Tris-HCI, pH 7.0). The 
reaction mixtures contained 0.1 ml plasma, 0.1 ml 
diluted thromboplastin, 0.1 ml osteocalcin i  buffer A 
or buffer A alone and 0.1 ml 30 mM CaC12. 
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orders of magnitude lower than that of the Gla- 
containing coagulation factors. 
4. DISCUSSION 
Osteocalcin is a protein of M, -5000 and con- 
tains 3 Gla residues on the same face of one helix, 
spaced at intervals of about 5.4 A [ 11). The M, 
values of the 4 vitamin K-dependent coagulation 
factors range between 50~ and 70000 and these 
proteins contain 10-12 Gla residues per molecule 
[3,10]. From these data it may be calculated that, 
when expressed as a percentage of the total amount 
of amino acid residues, the Gla content of 
osteocalcin is 3-4-times higher than that of the 
coagulation factors. When the presence of Gla 
residues is the only requirement for a protein to be 
able to bind to negatively charged phospholipids, 
one might therefore expect that the affinity of 
osteocalcin for phospholipid vesicles should not 
differ by many orders of magnitude from that of 
the coagulation factors. Nevertheless we have not 
been able to detect any competition between the 
phospholipid binding of coagulation factors and 
that of osteocalcin, ~though the latter was present 
in great excess. Therefore, we believe that an alter- 
native explanation for the role of Gla residues in 
the protein-phospholipid interaction should be 
considered. 
From the amino acid sequence in bovine pro- 
thrombin 1121 it may be readily seen that among 
the first 48 amino acid residues 10 Gla residues are 
found, together with 6 amino acids containing a 
positively charged side chain (fig.3). At a neutral 
pH, the net charge of this part of the molecule is 
strongly negative (- 15), whereas that of the rest of 
the fragment-l region is slightly positive (+ 3). Ob- 
viously, saturation of the Gla residues with Ca2’ 
will have a profound impact on the conformation 
and properties of the NHz-terminal part of the pro- 
thrombin molecule, because the net charge changes 
from - 15 to + 5. One of the results of this binding 
will be that the net charge of fragment-l as a whole 
is now + 8, with most of the positively charged side 
chains positioned at the NH2-terminus. Without 
doubt this structure will have a high affinity 
towards negatively charged phospholipids. The 
model also enables us to explain why descarbox- 
yprothrombin is inactive in the blood coagulation 
process: because of the relatively weak interaction 
PT - Ca” 
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Fig.3. Charge distribution in the NHz-terminal part of 
various proteins. Top to bottom: prothrombin in the 
absence of Ca’+, prothrombin in the presence of Ca2+, 
des~rboxyprothrombin in the absence and presence of 
Ca2+, osteocalcin the absence of Ca” and osteocalcin 
in the presence of Ca”. The amino acid sequence of 
prothrombin is from [I21 and that of osteocakin from 
1111. 
between Glu residues (instead of Gla) and Ca’+, 
these residues are not neutralized at physiological 
Ca2’ concentrations. As a result the net charge of 
the first 48 amino acid residues will be - 5 and no 
binding to phospholipids will occur. 
Similarly, it may be seen that the net charge of 
osteocalcin is -7 and after neutralization of its 3 
Gla residues a slightly negatively charged molecule 
still remains. So it is not expected that conditions 
can be found under which osteocalcin will bind to 
negatively charged phospholipids. It seems possi- 
ble, therefore, that Gla residues in a certain protein 
only serve to bind Ca”, whereas the eventual af- 
finity of the protein towards negatively charged 
phospholipids is related to the charge distribution 
in the rest of the molecule. Although the present 
results are far from complete and may hardly be 
used in favor of one of the models for 
protein-phospholipid interaction, we believe that 
the model explained in fig.3 should be taken into 
consideration for future investigations. 
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